Treatment development · updated November 9, 2026

Therapy pipeline

Major Phase 2, Phase 3 and regulatory-stage obesity programs, with linked studies across related health conditions. Browse by mechanism, then open a profile for the study-by-study view.

FDA-approved obesity medicines Compare label uses and the trials behind them.

47pipeline profiles
195 study records tracked
Updated November 9, 2026

A visual key

Explore by target

Explore the anatomy ↗

Choose a target to filter programs. Combinations may appear under more than one pathway; body composition and other targets are grouped separately.

Explore the programs

Obesity phase is shown by formulation and region where they differ.

47 of 47 pipeline profiles

Stages refer to obesity development, with formulation and regional context. Column spacing does not represent time to approval.

Amylin & combinations14 programs

GLP-1 / GIP10 programs

Phase 2

Full profile

Phase 3

Full profile

Filed for review

No selected programs

GIP-focused1 programs

Phase 2

Full profile

Phase 3

No selected programs

Filed for review

No selected programs

Glucagon-containing6 programs

Phase 2

Full profile

Phase 3

Full profile

Filed for review

No selected programs

GLP-1 focused11 programs

Phase 2

Full profile

Phase 3

Full profile

Filed for review

No selected programs

Body composition & other targets5 programs

Phase 2

Full profile

Phase 3

No selected programs

Filed for review

No selected programs

A curated inventory of major Phase 2, Phase 3 and regulatory-stage obesity programs, plus selected body-composition and other-target medicines. “Planned” does not mean initiated. Study-focus labels identify the condition or outcome a trial evaluates; they do not imply an approved use. A Phase 3 study in MASH or diabetes alone does not upgrade a drug’s obesity stage. Results across trials are not head-to-head comparisons. Approved therapies are covered on the approved-medicines page.